BlackRock Amends Rocket Pharma Stake to 9.0% as of Dec 31, 2023
Ticker: RCKTW · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still a major holder in Rocket Pharma, owning 9.0% as of year-end!**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in Rocket Pharmaceuticals, Inc. As of December 31, 2023, BlackRock held 6,293,925 shares of common stock, representing 9.0% of the company's outstanding shares. This is an amendment to a previous filing, indicating a change in their holdings. This matters to investors because BlackRock is a major institutional investor, and their significant stake and any changes in it can signal their confidence (or lack thereof) in Rocket Pharmaceuticals' future prospects.
Why It Matters
BlackRock's substantial 9.0% ownership in Rocket Pharmaceuticals signals strong institutional confidence, which can positively influence other investors and the stock's perceived stability.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investor maintains a significant stake, generally reducing perceived risk due to their due diligence.
Analyst Insight
Investors should note BlackRock's continued significant stake as a sign of institutional confidence, but also monitor future filings for any substantial changes in their position, which could signal a shift in their outlook on Rocket Pharmaceuticals.
Key Numbers
- 6,293,925 — shares owned by BlackRock (total number of common stock shares of Rocket Pharmaceuticals held by BlackRock Inc. as of December 31, 2023)
- 9.0% — percentage of class owned (the percentage of Rocket Pharmaceuticals' common stock owned by BlackRock Inc. as of December 31, 2023)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Rocket Pharmaceuticals, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will likely maintain a significant stake in Rocket Pharmaceuticals throughout 2024. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating a change in beneficial ownership by a passive institutional investor.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., a major asset management firm.
What company's shares are being reported in this filing?
The shares being reported belong to Rocket Pharmaceuticals, Inc., a pharmaceutical preparations company.
As of what date are the reported shareholdings accurate?
The reported shareholdings are accurate as of December 31, 2023, which is the 'Date of Event Which Requires Filing of this Statement'.
How many shares of Rocket Pharmaceuticals, Inc. does BlackRock Inc. beneficially own, and what percentage does this represent?
BlackRock Inc. beneficially owns 6,293,925 shares of Rocket Pharmaceuticals, Inc. common stock, which represents 9.0% of the class.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding ROCKET PHARMACEUTICALS, INC. (RCKTW).